This is particularly relevant in light of the frequently and severe reported hepatic toxicity related to the addition of a toxic compound to the CD33 targeting and subsequent calicheamicin accumulation and/or unwanted release and toxicity to normal cells surrounding CD33+ tumor cells. Here, CD33 is linked to neoplasm.